Headline: Auxilium Health raises $3.4M seed round to advance Aer™ bioaerogel toward FDA and first-in-human trials
Auxilium Health closed an oversubscribed $3.4 million seed round on July 14, 2026, to accelerate development of its Aer™ biomaterials platform with the explicit goal of pursuing FDA authorization and first-in-human studies. The financing—completed a year after a pre-seed round—more than doubled the prior raise and reflects renewed confidence from regional and strategic investors, both existing and new.
Funding to push product into the clinic
The new capital will be used to advance Auxilium’s lead product toward regulatory validation and the initiation of clinical trials. The company says the funds will also support headcount growth and deeper R&D on the Aer™ platform, which has prior backing from the National Science Foundation, the Ohio Department of Development and the Polymer Industry Cluster.
A different tactic against bacterial colonization
Auxilium is positioning Aer™ as a departure from conventional biomaterials strategies that focus on eliminating bacteria after they arrive. Aer™ is described as a biomimetic matrix—a bioaerogel—designed to mimic the extracellular matrix and “win the race to the surface” by preventing bacterial attachment while promoting patient cell adhesion and tissue regeneration, all without relying on antibiotics.
Targets: FDA filing and first-in-human trials
The company’s stated objective is to reach a stage of regulatory clarity—including a submission to the FDA—and to prepare for initial human trials. Auxilium notes that, despite scientific questions raised last year, investor and market perception has shifted in favor of rapid implementation to get the technology to patients.
Team growth and local anchoring
Over the past 12 months Auxilium says it has doubled full-time headcount, recruiting researchers and scientists who relocated to Cleveland. The startup is based in the Cleveland Clinic’s Global Innovation Center, a location that strengthens access to clinical resources and the local innovation ecosystem.
Product scope and market context
Auxilium is developing a family of bioaerogels aimed at reducing bacterial colonization risk while guiding tissue regeneration, with applications spanning wound repair, bone regeneration and local delivery of therapeutics. The $3.4M seed is intended to advance these ambitions in the near term.
This financing comes amid growing interest in material-based alternatives to antibiotics for preventing device- and implant-associated infections. Auxilium is placing its Aer™ platform at the center of that strategy.
Source: Auxilium Health press release — https://www.auxiliumhealth.xyz/
